
Axel Benner

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5859834/publications.pdf Version: 2024-02-01



AVEL RENNED

#	Article	IF	CITATIONS
1	Genomic Aberrations and Survival in Chronic Lymphocytic Leukemia. New England Journal of Medicine, 2000, 343, 1910-1916.	13.9	2,967
2	DNA methylation-based classification of central nervous system tumours. Nature, 2018, 555, 469-474.	13.7	1,872
3	Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia. New England Journal of Medicine, 2008, 358, 1909-1918.	13.9	1,514
4	Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood, 2002, 100, 4372-4380.	0.6	794
5	11q Deletions Identify a New Subset of B-Cell Chronic Lymphocytic Leukemia Characterized by Extensive Nodal Involvement and Inferior Prognosis. Blood, 1997, 89, 2516-2522.	0.6	363
6	Differential impact of allelic ratio and insertion site in FLT3-ITD–positive AML with respect to allogeneic transplantation. Blood, 2014, 124, 3441-3449.	0.6	350
7	Tumor-derived exosomes modulate PD-L1 expression in monocytes. Science Immunology, 2017, 2, .	5.6	236
8	Midostaurin added to chemotherapy and continued single-agent maintenance therapy in acute myeloid leukemia with FLT3-ITD. Blood, 2019, 133, 840-851.	0.6	228
9	Prospective Evaluation of Allogeneic Hematopoietic Stem-Cell Transplantation From Matched Related and Matched Unrelated Donors in Younger Adults With High-Risk Acute Myeloid Leukemia: German-Austrian Trial AMLHD98A. Journal of Clinical Oncology, 2010, 28, 4642-4648.	0.8	205
10	Gene mutations and response to treatment with all-trans retinoic acid in elderly patients with acute myeloid leukemia. Results from the AMLSG Trial AML HD98B. Haematologica, 2009, 94, 54-60.	1.7	195
11	Translocation t(11;14) Is Associated With Adverse Outcome in Patients With Newly Diagnosed AL Amyloidosis When Treated With Bortezomib-Based Regimens. Journal of Clinical Oncology, 2015, 33, 1371-1378.	0.8	185
12	Impact of NPM1/FLT3-ITD genotypes defined by the 2017 European LeukemiaNet in patients with acute myeloid leukemia. Blood, 2020, 135, 371-380.	0.6	127
13	T25 Repeat in the 3′ Untranslated Region of the CASP2 Gene: A Sensitive and Specific Marker for Microsatellite Instability in Colorectal Cancer. Cancer Research, 2005, 65, 8072-8078.	0.4	125
14	Drug-perturbation-based stratification of blood cancer. Journal of Clinical Investigation, 2017, 128, 427-445.	3.9	124
15	Machine learning workflows to estimate class probabilities for precision cancer diagnostics on DNA methylation microarray data. Nature Protocols, 2020, 15, 479-512.	5.5	89
16	Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis, 2014, 21, 9-17.	1.4	84
17	Gemtuzumab Ozogamicin in <i>NPM1</i> Mutated Acute Myeloid Leukemia: Early Results From the Prospective Randomized AMLSG 09-09 Phase III Study. Journal of Clinical Oncology, 2020, 38, 623-632.	0.8	73
18	Impact of gemtuzumab ozogamicin on MRD and relapse risk in patients with <i>NPM1</i> -mutated AML: results from the AMLSG 09-09 trial. Blood, 2020, 136, 3041-3050.	0.6	73

Axel Benner

#	Article	IF	CITATIONS
19	Highâ€Dimensional Cox Models: The Choice of Penalty as Part of the Model Building Process. Biometrical Journal, 2010, 52, 50-69.	0.6	69
20	Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood, 2016, 128, 594-602.	0.6	67
21	Daratumumab for systemic AL amyloidosis: prognostic factors and adverse outcome with nephrotic-range albuminuria. Blood, 2020, 135, 1517-1530.	0.6	67
22	All-trans retinoic acid as adjunct to intensive treatment in younger adult patients with acute myeloid leukemia: results of the randomized AMLSG 07-04 study. Annals of Hematology, 2016, 95, 1931-1942.	0.8	61
23	Genomic heterogeneity in core-binding factor acute myeloid leukemia and its clinical implication. Blood Advances, 2020, 4, 6342-6352.	2.5	45
24	Molecular landscape and prognostic impact of FLT3-ITD insertion site in acute myeloid leukemia: RATIFY study results. Leukemia, 2022, 36, 90-99.	3.3	42
25	Relapsed/refractory acute myeloid leukemia: any progress?. Current Opinion in Oncology, 2017, 29, 467-473.	1.1	39
26	Isatuximab, carfilzomib, lenalidomide, and dexamethasone (Isa-KRd) in front-line treatment of high-risk multiple myeloma: interim analysis of the GMMG-CONCEPT trial. Leukemia, 2022, 36, 885-888.	3.3	38
27	SNPs in transporter and metabolizing genes as predictive markers for oxaliplatin treatment in colorectal cancer patients. International Journal of Cancer, 2016, 138, 2993-3001.	2.3	34
28	Performance analysis of AL amyloidosis cardiac biomarker staging systems with special focus on renal failure and atrial arrhythmia. Haematologica, 2019, 104, 1451-1459.	1.7	29
29	Pretransplant Vitamin D Deficiency Is Associated With Higher Relapse Rates in Patients Allografted for Myeloid Malignancies. Journal of Clinical Oncology, 2017, 35, 3143-3152.	0.8	27
30	Evaluation and Validation of Plasma Proteins Using Two Different Protein Detection Methods for Early Detection of Colorectal Cancer. Cancers, 2019, 11, 1426.	1.7	27
31	Midostaurin plus intensive chemotherapy for younger and older patients with AML and <i>FLT3</i> internal tandem duplications. Blood Advances, 2022, 6, 5345-5355.	2.5	24
32	Multiplex screening of 275 plasma protein biomarkers to identify a signature for early detection of colorectal cancer. Molecular Oncology, 2020, 14, 8-21.	2.1	23
33	Multi-platform profiling characterizes molecular subgroups and resistance networks in chronic lymphocytic leukemia. Nature Communications, 2021, 12, 5395.	5.8	15
34	<scp>Daratumumab, lenalidomide, and dexamethasone</scp> in systemic <scp>light hain</scp> amyloidosis: High efficacy, relevant toxicity and main adverse effect of gain 1q21. American Journal of Hematology, 2021, 96, E253-E257.	2.0	13
35	Applying stability selection to consistently estimate sparse principal components in high-dimensional molecular data. Bioinformatics, 2015, 31, 2683-2690.	1.8	12
36	Polymorphisms in the Angiogenesis-Related Genes EFNB2, MMP2 and JAG1 Are Associated with Survival of Colorectal Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 5395.	1.8	12

Axel Benner

#	Article	IF	CITATIONS
37	Lenalidomide and dexamethasone in relapsed/refractory immunoglobulin light chain (AL) amyloidosis: results from aÂlarge cohort of patients with long followâ€up. British Journal of Haematology, 2021, 195, 230-243.	1.2	11
38	Prediction accuracy and variable selection for penalized causeâ€specific hazards models. Biometrical Journal, 2018, 60, 288-306.	0.6	7
39	Addition of cyclophosphamide on insufficient response to pomalidomide and dexamethasone: results of the phase II PERSPECTIVE Multiple Myeloma trial. Blood Cancer Journal, 2019, 9, 45.	2.8	7
40	Marginal variable screening for survival endpoints. Biometrical Journal, 2020, 62, 610-626.	0.6	7
41	Bortezomib-based induction, high-dose melphalan and lenalidomide maintenance in myeloma up to 70 years of age. Leukemia, 2021, 35, 809-822.	3.3	7
42	Validation of Genetic Markers Associated with Survival in Colorectal Cancer Patients Treated with Oxaliplatin-Based Chemotherapy. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 352-361.	1.1	7
43	Adjusting Simon's optimal twoâ€stage design for heterogeneous populations based on stratification or using historical controls. Biometrical Journal, 2020, 62, 311-329.	0.6	6
44	Dissecting the Prognostic Significance and Functional Role of Progranulin in Chronic Lymphocytic Leukemia. Cancers, 2019, 11, 822.	1.7	5
45	Genotype-Based Gene Expression in Colon Tissue—Prediction Accuracy and Relationship with the Prognosis of Colorectal Cancer Patients. International Journal of Molecular Sciences, 2020, 21, 8150.	1.8	4
46	Prognostic Impact of Serum Free Light Chain Ratio Normalization in Patients with Multiple Myeloma Treated within the GMMG-MM5 Trial. Cancers, 2021, 13, 4856.	1.7	3
47	A consistent version of distance covariance for rightâ€censored survival data and its application in hypothesis testing. Biometrics, 2022, 78, 867-879.	0.8	2
48	Genetic Variants in the Regulatory T cell–Related Pathway and Colorectal Cancer Prognosis. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2719-2728.	1.1	1
49	Three brief pieces of statistical advice for medical peer reviewers. European Journal of Clinical Investigation, 2019, 49, e13171.	1.7	0
50	Computational Statistics Solutions for Molecular Biomedical Research: A Challenge and Chance for Both. , 2010, , 19-32.		0